• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Braftovi (encorafenib) + Mektovi (binimetinib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Braftovi (encorafenib) + Mektovi (binimetinib)

  • Profile

Profile

Contact Information

Contact: Pfizer
Website: www.braftovimektovi.com

Currently Enrolling Trials

    Show More

    General Information

    Braftovi (encorafenib) is an oral small molecule BRAF kinase inhibitor. Mektovi (binimetinib) is an oral small molecule MEK inhibitor which target key enzymes in the MAPK signaling pathway (RAS-RAF-MEK-ERK). 

    Braftovi + Mektovi is specifically indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

    Braftovi is supplied as a capsule for oral administration. Mektovi is supplied as a tablet for oral administration. The recommended dosage of Braftovi is 450 mg orally taken once daily in combination with binimetinib until disease progression or unacceptable toxicity. Braftovi may be taken with or without food. Do not take a missed dose of Braftovi within 12 hours of the next dose of Braftovi. Do not take an additional dose if vomiting occurs after Braftovi administration but continue with the next scheduled dose. The recommended dosage of Mektovi is 45 mg orally taken twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. Mektovi may be taken with or without food. Do not take a missed dose of Mektovi within 6 hours of the next dose of Mektovi. Do not take an additional dose if vomiting occurs after Mektovi administration but continue with the next scheduled dose. 

    Mechanism of Action

    Braftovi (encorafenib) is an oral small molecule BRAF kinase inhibitor. Mektovi (binimetinib) is an oral small molecule MEK inhibitor which target key enzymes in the MAPK signaling pathway (RAS-RAF-MEK-ERK). 

    Side Effects

    Adverse effects associated with the use of Braftovi + Mektovi may include, but are not limited to, the following:

    • fatigue
    • nausea
    • vomiting
    • abdominal pain
    • arthralgia

    Clinical Trial Results

    The FDA approval of Braftovi and Mektovi was based on a randomized, active-controlled, open-label, multicenter trial (COLUMBUS). Patients were required to have BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. Patients were permitted to have received immunotherapy in the adjuvant setting and one prior line of immunotherapy for unresectable locally advanced or metastatic disease. Prior use of BRAF inhibitors or MEK inhibitors was prohibited. Patients were randomized (1:1:1) to receive Braftovi 450 mg once daily in combination with binimetinib 45 mg twice daily, Braftovi 300 mg once daily, or vemurafenib 960 mg twice daily. Treatment continued until disease progression or unacceptable toxicity. Only the results of the approved dosing (Braftovi 450 mg in combination with binimetinib 45 mg) are described below. The major efficacy outcome measure was progression-free survival (PFS) of Braftovi in combination with binimetinib compared with vemurafenib as assessed by a blinded independent central review. Braftovi in combination with binimetinib demonstrated a statistically significant improvement in PFS compared to vemurafenib (14.9 vs. 7.3 months). In addition, patients in the combination therapy arm demonstrated superior overall response rate (63% vs. 40%), a longer duration of response (51 weeks vs. 31 weeks) and received a higher median dose intensity (100% vs. 99.6%) compared with the vemurafenib arm.

    Approval Date: 2018-06-01
    Company Name: Pfizer
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing